Globalization’s Resiliance is Partly Tax

  • Globalization has also persisted because the Trump-Ryan reforms to the U.S. corporate tax system, implemented through the Tax Cuts and Jobs Act (TCJA), did not end tax-related incentives for U.S. firms to offshore production and profits.
  • A reversal of the latter could be an issue for big pharma and semiconductor firms.
  • China’s export-led growth strategy is the other, admittedly larger, driver.
  • Blog post here and full paper here.

The Rise of Chinese Biotech

  • China is making immense progress in many fields. Biotechnology is no exception.
  • A 2024 IQVIA report shows that the share of clinical trials launched by Chinese-headquartered biopharmaceutical companies rose from 3 percent in 2013 to 28 percent in 2023, suggesting a growing involvement of Chinese companies in early-phase drug development.
  • More interesting charts on the topic here.
WordPress Cookie Notice by Real Cookie Banner